Evidence map›Paper›PMID 35977459›Full record

ArticleThe International journal on drug policy2022

Barriers to engaging people who use drugs in harm reduction services during the COVID-19 pandemic: A mixed methods study of syringe services program perspectives.

Elizabeth J Austin, Maria A Corcorran, Elsa S Briggs, Madeline C Frost, Czarina N Behrends, Alexa M Juarez, Noah D Frank, Elise Healy, Stephanie M Prohaska, Paul A LaKosky and 6 more

Open access · greenAbstract read
In one paragraph

Article in The International journal on drug policy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 1 country.

Elizabeth J AustinDepartment of Health Systems and Population Health, University of Washington, 3980 15th Ave NE, Seattle, WA, USA. Electronic address: austie@uw.edu.
Maria A CorcorranDivision of Allergy and Infectious Diseases, Department of Medicine, University of Washington, 1959 Pacific Street NE, Seattle, WA, USA.
Elsa S BriggsDepartment of Health Systems and Population Health, University of Washington, 3980 15th Ave NE, Seattle, WA, USA.
Madeline C FrostDepartment of Health Systems and Population Health, University of Washington, 3980 15th Ave NE, Seattle, WA, USA; Health Services Research & Development Center of Innovation for Veteran-Centered and Value-Driven Care, Veterans Affairs Puget Sound Health Care System, 1660 S Columbian Way, Seattle, WA, USA.
Czarina N BehrendsDepartment of Population Health Sciences, Weill Cornell Medical College, 1300 York Avenue, New York, NY, USA.
Alexa M JuarezDivision of Allergy and Infectious Diseases, Department of Medicine, University of Washington, 1959 Pacific Street NE, Seattle, WA, USA.
Noah D FrankDivision of Allergy and Infectious Diseases, Department of Medicine, University of Washington, 1959 Pacific Street NE, Seattle, WA, USA.
Elise HealyDivision of Allergy and Infectious Diseases, Department of Medicine, University of Washington, 1959 Pacific Street NE, Seattle, WA, USA.
Stephanie M ProhaskaDave Purchase Project, North American Syringe Exchange Network, 535 Dock Street, Tacoma, WA, USA.
Paul A LaKoskyDave Purchase Project, North American Syringe Exchange Network, 535 Dock Street, Tacoma, WA, USA.
Shashi N KapadiaDepartment of Population Health Sciences, Weill Cornell Medical College, 1300 York Avenue, New York, NY, USA; Division of Infectious Diseases, Weill Cornell Medical College, 1300 York Avenue, New York, NY, USA.
David C PerlmanCenter for Drug Use and HIV Research, School of Global Public Health, New York University, 708 Broadway, New York, NY, USA; Division of Infectious Diseases, Mount Sinai Beth Israel, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, New York, NY, USA.
Bruce R SchackmanDepartment of Population Health Sciences, Weill Cornell Medical College, 1300 York Avenue, New York, NY, USA.
Don C Des JarlaisSchool of Global Public Health, New York University, 708 Broadway, New York, NY, USA.
Emily C WilliamsDepartment of Health Systems and Population Health, University of Washington, 3980 15th Ave NE, Seattle, WA, USA; Health Services Research & Development Center of Innovation for Veteran-Centered and Value-Driven Care, Veterans Affairs Puget Sound Health Care System, 1660 S Columbian Way, Seattle, WA, USA.
Sara N GlickDivision of Allergy and Infectious Diseases, Department of Medicine, University of Washington, 1959 Pacific Street NE, Seattle, WA, USA.
University of Washington · USCornell University · USScience Exchange (United States) · USHealth Services Research & Development · USIcahn School of Medicine at Mount Sinai · USNew York University · US

Funding

Transdisciplinary Theoretical Svnthesis and Development CoreP30DA011041 · NIDA · NEW YORK UNIVERSITY · PI Holly Hagan, Courtney McKnight · 1998 to 2026
$38.9M
Utilization of health services after engagement with opioid use disorder (OUD) treatment provider by individuals with and without post-traumatic stress disorderP30DA040500 · NIDA · WEILL MEDICAL COLL OF CORNELL UNIV · PI ZACHARY Franklin MEISEL · 2015 to 2026
$20.7M
Economic Analysis of Rapid HIV and HCV Testing in Drug Abuse Treatment ProgramsR01DA027379 · NIDA · WEILL MEDICAL COLL OF CORNELL UNIV · PI SCHACKMAN, BRUCE R · 2009 to 2021
$5.3M
Integrated Care for Hepatitis C: Current Uptake & Impact on Future TreatmentK01DA048172 · NIDA · WEILL MEDICAL COLL OF CORNELL UNIV · PI KAPADIA, SHASHI · 2019 to 2023
$948k
NIDA NIH HHS K01 DA048172NIDA NIH HHS P30 DA011041NIDA NIH HHS P30 DA040500NIDA NIH HHS R01 DA027379
6 · The paper itself

Abstract

backgroundSyringe services programs (SSPs) provide critical evidence-based public health services that decrease harms from drug use for people who use drugs (PWUD). Many SSPs have experienced significant and evolving COVID-19-related disruptions. We aimed to characterize the impacts of COVID-19 on SSP operations in the United States approximately one year into the pandemic.

methodsParticipating sites, selected from a national sample of SSPs, completed a semi-structured interview via teleconference and brief survey evaluating the impacts of COVID-19 on program operations. Data collection explored aspects of program financing, service delivery approaches, linkages to care, and perspectives on engaging PWUD in services one year into the pandemic. Interview data were analyzed qualitatively using Rapid Assessment Process. Survey data were analyzed using descriptive statistics and triangulated with qualitative findings.

results27 SSPs completed study-related interviews and surveys between February 2021 - April 2021. One year into the pandemic, SSPs reported continuing to adapt approaches to syringe distribution in response to COVID-19, and identified multiple barriers that hindered their ability to engage program participants in services, including 1) isolation and decreased connectivity with participants, 2) resource restrictions that limit responsiveness to participant needs, 3) reduced capacity to provide on-site HIV/HCV testing and treatment linkages, and 4) changing OUD treatment modalities that were a "double-edged sword" for PWUD. Quantitative survey responses aligned with qualitative findings, highlighting increases in the number of syringes distributed, increases in mobile and home delivery services, and reductions in on-site HIV and HCV testing.

conclusionThese data illuminate persistent and cascading risks of isolation, reduced access to services, and limited engagement with program participants that resulted from COVID-19 and continue to create barriers to the delivery of critical harm reduction services. Findings emphasize the need to ensure SSPs have the resources and capacity to adapt to changing public health needs, particularly as the COVID-19 pandemic continues to evolve.

Indexed as

COVID-19Hepatitis CHIV InfectionsSubstance Abuse, IntravenousHarm ReductionHumansNeedle-Exchange ProgramsPandemicsSyringesUnited StatesCOVID-19Harm reductionPatient engagementSyringe services programs

Identifiers

PMID35977459
PMCPMC9364718
OpenAlexW4291475213

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.